Items where authors include "Vis, M."

Article

Palominos, P.E. orcid.org/0000-0003-0132-4325, Fernández-Ávila, D.G. orcid.org/0000-0003-1490-1822, Coates, L.C. orcid.org/0000-0002-4756-663X et al. (18 more authors) (2023) Management of dactylitis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations. The Journal of Rheumatology, 50 (2). pp. 265-278. ISSN 0315-162X

Conference or Workshop Item

Tillett, W.R., Coates, L., Vis, M. et al. (7 more authors) (2023) Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment. In: ACR Convergence 2023, 10-15 Nov 2023, San Diego, CA.

Tillett, W., Coates, L., Vis, M. et al. (7 more authors) (2023) POS1535 Early improvement in 3VAS/4VAS predicts reduced rates of radiographic change in bio-naive active psoriatic arthritis patients receiving Guselkumab treatment. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Proceedings Paper

Wells, A.F., Kavanaugh, A., Tillett, W. et al. (7 more authors) (2024) Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast. In: Arthritis & Rheumatology. ACR Convergence 2024, 14-19 Nov 2024, Washington, DC, USA. Wiley , pp. 1213-1215.

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2023) P176 Minimal important difference, minimal detectable change and disease activity thresholds for two novel composite instruments, three visual analogue scale/VAS and four visual analogue scale/VAS, in patients with psoriatic arthritis: pooled analysis of three phase III studies. In: Rheumatology. British Society for Rheumatology Annual Conference 2023, 24-26 Apr 2023, Manchester, UK. Oxford University Press .

Tillett, W., Coates, L., Vis, M. et al. (9 more authors) (2022) 1017: Minimal Important Difference (MID), Minimal Detectable Change (MDC),and Disease Activity Thresholds for Two Novel Composite Instruments(3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of ThreePhase 3 Studies. In: Arthritis & Rheumatology. ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, USA. Wiley , pp. 2013-2015.